News

July 15, 2022

Eric Shiozaki, PhD

Eric is a Partner at DCVC Bio, a life science venture capital firm. Previously, he was a Partner at Novo Ventures where he helped establish and managed the firm’s public equities strategy focused on smidcap and late-stage private companies in biotech and medtech. Earlier in his career he was a Director at Apposite Capital after…

July 15, 2022

Rami Hannoush, PhD

Dr. Hannoush is a general partner at Mubadala Capital, the financial investment arm of the Sovereign Wealth Fund Mubadala. He co-heads the ventures healthcare investment platform and oversees its strategy, and also leads the firm’s efforts in life sciences company creation. Prior to his current position, Dr. Hannoush spent fifteen years at Genentech where he…

July 15, 2022

Marianne Mertens, PhD

Marianne is a Partner at Apollo Health Ventures and responsible for Apollo’s investment and company building activities. Prior to joining the Apollo team, Marianne was a Principal with Wellington Partners, a pan-European Venture Capital firm investing in early- and growth-stage Life Science companies. In this role she led Wellington’s investments in Confo Therapeutics and Imcheck…

June 7, 2022

Alexandra Cantley, PhD

Alexandra joined Polaris Partners in 2019 and serves as a partner in the New York office. She is primarily focused on early stage biotech and healthcare investments. She currently serves on the Board of Directors of BeMeHealth, Podimetrics, SunBird Bio, and Trex Bio, and as a Board Observer to Engine Bio. Prior to joining Polaris,…

May 20, 2022

Brad Robling

Brad Robling is the Vice President of Corporate Business Development / Lilly New Ventures at Eli Lilly and Company. As such, he is focused on managing Eli Lilly’s venture capital investments globally. Prior to joining the Eli Lilly venture team, he held positions in business development and investor relations.  Prior to joining Lilly, he held…

May 20, 2022

Briggs Morrison, MD

Dr. Morrison received his B.S. in biology from Georgetown University, his M.D. from the University of Connecticut Medical School, completed residency training in Internal Medicine at the Massachusetts General Hospital, and completed a fellowship in Medical Oncology at Dana-Farber Cancer Institute. He did postdocs with Philip Leder at Harvard Medical School, and Lee Nadler at…

May 20, 2022

Alon Lazarus, PhD

Dr. Alon Lazarus joined Arkin Holdings’ pharma division in 2013. He serves on the board of several of Arkin’s pharmaceutical companies, including Keros Therapeutics, and Lutris Pharma. Prior to joining Arkin, Dr. Lazarus worked for the healthcare business development department of Yissum, the R&D arm of the Hebrew University of Jerusalem. Dr. Lazarus holds a…

May 20, 2022

Anna French, PhD

Anna French, PhD is a Partner at Qiming Venture Partners USA, and is based in Cambridge, MA. Prior to joining the Qiming team in 2017, Anna was a management consultant at the Boston Consulting Group (BCG) where she advised leading biopharma companies on their strategy and operations. She also led a global industry-academic consortium focused…